Company Data
Aerovate Therapeutics Inc.
Ticker
AVTE
Price Target
Refer to Report
Volume
1
52wk Range
$1.25 - $25.285
Overview
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe.